drugset / Trial / NCT00823862
Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Phase 1
Completed
34 enrolled
Dynavax Technologies Corporation
PPD Development, LP · collabSynteract, Inc. · collab
RandomizedSingle-groupSingle-blindTreatment
Summary
To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-12
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nelitolimod | Oligonucleotide (other) | — | Intramuscular |
| Background | Ribavirin | Small molecule | — | Oral |